RMD - ResMed Inc.
| Previous Close | 103.74 |
| Open | 103.21 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 3100 |
| Day's Range | 101.04 - 103.94 |
| 52 Week Range | 82.81 - 116.64 |
| Volume | 751,345 |
| Avg. Volume | 712,635 |
| Market Cap | 14.492B |
| Beta (3Y Monthly) | 1.19 |
| PE Ratio (TTM) | 46.44 |
| EPS (TTM) | 2.19 |
| Earnings Date | Jan 21, 2019 - Jan 25, 2019 |
| Forward Dividend & Yield | 1.48 (1.43%) |
| Ex-Dividend Date | 2018-11-07 |
| 1y Target Est | 104.80 |
- Simply Wall St.•16 hours ago
Is ResMed Inc’s (NYSE:RMD) CEO Incentives Align With Yours?
Mick Farrell has been the CEO of ResMed Inc (NYSE:RMD) since 2013. First, this article will compare CEO compensation with compensation at other large companies. Next, we’ll consider growth that Read More...
Markit•6 days agoSee what the IHS Markit Score report has to say about ResMed Inc.
ResMed Inc NYSE:RMD
- Zacks•7 days ago
ResMed's Out-of-Hospital Line to Grow With MatrixCare Buyout
MatrixCare consolidation is expected to enhance ResMed's (RMD) capacity to improve patient transitions of care as well as its provider skills.
- Business Wire•9 days ago
ResMed to Acquire MatrixCare, Expands Out-of-Hospital SaaS Portfolio into Long-Term Care Settings
.@ResMed to acquire @MatrixCare, expands out-of-hospital #SaaS portfolio into long-term care settings #HealthIT #skillednursing #seniorliving #homecare
Markit•14 days agoSee what the IHS Markit Score report has to say about ResMed Inc.
ResMed Inc NYSE:RMD
- GlobeNewswire•15 days ago
Research Report Identifies Charter Communications, Old Dominion Freight Line, CoreLogic, Align Technology, HealthStream, and ResMed with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•16 days ago
ResMed (RMD) Looks Good: Stock Adds 5.7% in Session
ResMed (RMD) shares rose nearly 6% in the last trading session, amid huge volumes.
- Motley Fool•18 days ago
ResMed Starts Its Fiscal Year Strong
Broad-based sales growth propelled the medical device company to a 23% increase in profits.
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of RMD earnings conference call or presentation 25-Oct-18 8:30pm GMT
Q1 2019 Resmed Inc Earnings Call
- Zacks•19 days ago
ResMed (RMD) Q1 Earnings & Sales Beat on Overall Growth
ResMed (RMD) sees solid contributions from domestic and international businesses in Q1.
Motley Fool•19 days agoResMed Inc (RMD) Q1 2019 Earnings Conference Call Transcript
RMD earnings call for the period ending September 30, 2018.
- Zacks•19 days ago
ResMed (RMD) Q1 Earnings and Revenues Surpass Estimates
ResMed (RMD) delivered earnings and revenue surprises of 1.25% and 2.02%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•19 days ago
ResMed: Fiscal 1Q Earnings Snapshot
The San Diego-based company said it had net income of 73 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, came to 81 cents per share. The results surpassed Wall Street ...
- Business Wire•19 days ago
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2019
~ Strong year-over-year growth in revenue, net income, and earnings per share ~
- Simply Wall St.•21 days ago
Could The ResMed Inc (NYSE:RMD) Ownership Structure Tell Us Something Useful?
Every investor in ResMed Inc (NYSE:RMD) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in Read More...
- Zacks•21 days ago
Medical Product Earnings Lineup for Oct 25: SYK, CERN & More
Long-term potential of the Medical Products industry looks promising at the moment amid certain short-term geopolitical insecurities.
- Business Wire•22 days ago
ResMed Wins German Patent Infringement Case Against Fisher & Paykel
Court finds headgear used on Simplus and Eson 2 CPAP masks infringes ResMed patent
- Simply Wall St.•29 days ago
Does ResMed Inc’s (NYSE:RMD) Past Performance Indicate A Weaker Future?
When ResMed Inc (NYSE:RMD) released its most recent earnings update (30 June 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry Read More...
- Business Wire•29 days ago
Brightree Launches First Patient App for HME
Brightree®, the leading provider of cloud-based software to help post-acute care companies improve business performance and patient outcomes, announced today from Medtrade the release of its new Patient Hub to personalize the patient experience and increase revenue for home medical equipment (HME) providers. Patient Hub is a patient engagement app that automates and simplifies how HME providers connect with their patients. It eliminates the need for multiple web portals and consolidates all patient interactions into one secure platform.
- Business Wire•last month
AirFit F30, ResMed’s First Minimal-Contact Full Face CPAP Mask, Now Available in the U.S., Canada
Nearly 2 to 1 patients prefer AirFit F30 over the current minimal-contact full face market leader
- Reuters•last month
USITC to investigate Resmed for alleged patent infringement
The U.S. International Trade Commission said on Friday it would investigate California-based Resmed Inc for a patent infringement complaint related to sleep apnea mask systems. The investigation is based ...
- Business Wire•last month
ResMed to Announce First Quarter Fiscal 2019 Results
ResMed today announced it will report its first quarter of fiscal year 2019 results on Thursday, October 25, 2018, after the New York Stock Exchange market closes.
Market Realist•2 months agoWhat ResMed’s Valuation Trend Indicates
Ten analysts covered ResMed (RMD) in September. Four analysts gave ResMed stock a “buy” or higher rating, five analysts gave it a “hold” rating, and one analyst gave it a “strong sell” rating. The mean rating for ResMed stock is 2.6, and its target price is $104.69.
- Market Realist•2 months ago
Exploring ResMed’s Operational Performance
ResMed (RMD) incurred SG&A (selling, general, and administrative) expenses of $600.37 million in fiscal 2018, compared with $553.97 million in fiscal 2017. This increase was due to higher expenses related to doubtful debts and personnel for supporting commercial activities.
- CNBC Videos•19 days ago
How ResMed is benefiting from ageing demographics
Mick Farrell of ResMed says ageing populations have contributed to the growth of the company's two "core markets."
